Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response..

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

(Print or Ty	pe Kesponse	(S)														
1. Name and Address of Reporting Person * CICIC DRAGAN				2. Issuer Name and Ticker or Trading Symbol Actinium Pharmaceuticals, Inc. [ATNM]						5. Re	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O ACTINIUM PHARMACEUTICALS, INC, 275 MADISON AVENUE, 7TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 03/14/2017						X						
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
NEW YO	ORK, NY 1	0016										om med by	wore than One	reporting reison		
(Cit	y)	(State)	(Zip)			Tabl	e I -	Non-Deriva	tive Securi	ties Acq	quired,	Disposed	l of, or Ben	eficially Ow	ned	
1.Title of S (Instr. 3)	I.Title of Security Instr. 3)		Date (Month/Day/Year)			ate, if Co	(Instr. 8)				5. Amount of Securities Be Owned Following Reported Transaction(s)		ed O	Ownership Form:	eneficial	
				(Month/I	Oay/		Cod	e V Ar	nount (A)			or Indirect (I)		Ownership Instr. 4)		
	report on a			Derivativ	e Se	curities A	Acqu	Persons contain	s who respect in this splays a c	form ai urrently Seneficia	re not by valid	required OMB co	n of inform I to respoi ontrol nun	nd unless t		174 (9-02)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	if Transaction of Code Derry (Instr. 8) Sector (A) Dispute (D) (Instr. 8)		Derivati Securitie Acquire (A) or Dispose	ve es d	Expiration	. Date Exercisable and xpiration Date Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	e	Amount or Number of Shares				
Options to purchase common stock	\$ 1.39	03/14/2017		A		75,000		(1)	03/14/20	27	mmon tock	75,000	\$ 1.39	75,000	D	

Reporting Owners

Reporting Owner Name / Address		Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
CICIC DRAGAN C/O ACTINIUM PHARMACEUTICALS, INC 275 MADISON AVENUE, 7TH FLOOR NEW YORK, NY 10016			Chief Technology Officer				

Signatures

/s/ Dragan Cicic	03/16/2017
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.